Hepatosplenic T-cell lymphoma is a rare form of non-Hodgkin lymphoma,
which carries a poor prognosis. We report our single-institution experience in
the management of hepatosplenic T-cell lymphoma (HSTCL)- in 14 patients (pts)
among whom 7 who remain alive (50%) and in remission at a median
follow-up of 66 months. More frequent long-term survival was seen in those
treated with a non-CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone)
induction and consolidative stem cell transplant (SCT).
Introduction
Hepatosplenic T-cell lymphoma is a rare form of extranodal
non-Hodgkin lymphoma, first recognized as a distinct entity in the Revised
European-American Lymphoma classification. Typical presentation includes
lymphomatous infiltration of spleen and liver, and peripheral
lymphadenopathy is rarely seen. The prognosis is almost uniformly poor, and
there are no prospective studies of treatment of HSTCL.
Patients and Methods
For this report, we conducted a retrospective review of all pts who
underwent treatment for HSTCL at our institution. Individual chart review
was performed to report clinical presentation, management, and outcome.
Results
We identified 14 pts with HSTCL managed at our center, 7 of which
remain alive with median follow-up of 65.6 months. Six of 7 received
alternative induction chemotherapy regimens such as ICE (ifosfamide,
carboplatin, etoposide) or IVAC (ifosfamide, etoposide, high-dose
cytarabine) as opposed to CHOP and all surviving pts had proceeded to
undergo either autologous or allogeneic SCT.
Conclusion
Our results suggest that use of non-CHOP induction regimen and early
use of high dose therapy and SCT consolidation may translate to improved
survival for pts with HSTCL.